Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + obinutuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination of **polatuzumab vedotin** (a CD79b-directed antibody-drug conjugate) and **obinutuzumab** (a glycoengineered type II anti-CD20 monoclonal antibody), developed for hematological malignancies, particularly B-cell non-Hodgkin lymphomas. **Polatuzumab vedotin** targets CD79b on B cells and delivers the cytotoxic agent monomethyl auristatin E (MMAE), inducing apoptosis in dividing malignant B cells. **Obinutuzumab** binds CD20 on B cells, promoting antibody-dependent cellular cytotoxicity and direct cell death. This combination has been studied for its enhanced antitumor activity and tolerability, especially in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma (DLBCL)[1][3][5][6].
- Brand names
- None identified
- Other names
- pola-Gpolatuzumab vedotin plus obinutuzumabobinutuzumab plus polatuzumab vedotin
02
Targets
TUBB (Tubulin (alpha and beta subunits))B-cell antigen receptor complex-associated protein beta chainCD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on polatuzumab vedotin + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + obinutuzumab.